Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.

By M. Reck, R. Kaiser, A. Mellemgaard, J. Douillard, S. Orlov, M. Krzakowski, J. von Pawel, M. Gottfried, I. Bondarenko, M. Liao and 4 more. The Lancet Oncology, 2014

889 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/6fed713f6350709e7c92ba081165ecc20d77edb2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. A. Adamis
2. N. Ferrara
3. K. Kerr
4. M. Hellmann
5. Razelle Kurzrock
6. Daniel Chen
7. R. Apte

In Pulmonary and Respiratory Medicine

1. N. Ferrara

Citations in the corpus

• Ten years of anti-vascular endothelial growth factor therapy (2016, background): “…Boehringer Ingelheim Pharmaceuticals), a VEGFR–PDGFR–FGFR RTKI 132 , which recently demonstrated an OS benefit in patients with NSCLC in combination with doxacetal, compared with doxacetal alone (LUME Lung 1 study) in second-line therapy 133 , leading to its approval by the EMA in November 2014.”
• Nivolumab versus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer (2015, background): “Decreased appetite 30 (10) 0 42 (16) 3 (1)”
• Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “Again, improved efficacy was seen in the poor prognostic group of patients with nonresponding or fast progressing tumours [159, 160].”
• The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing (2015, result): “For example, the results of at least two phase III clinical trials of the multikinase inhibitor nintedanib (which targets FGFR, VEGFR, and PDGFR) in NSCLC showed statistically significant, albeit modest, benefit (42, 43).”